Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 4;112(23):3877-3896.e8.
doi: 10.1016/j.neuron.2024.09.006. Epub 2024 Sep 30.

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

Affiliations

Alzheimer's disease-linked risk alleles elevate microglial cGAS-associated senescence and neurodegeneration in a tauopathy model

Gillian K Carling et al. Neuron. .

Abstract

The strongest risk factors for late-onset sporadic Alzheimer's disease (AD) include the ε4 allele of apolipoprotein E (APOE), the R47H variant of triggering receptor expressed on myeloid cells 2 (TREM2), and female sex. Here, we combine APOE4 and TREM2R47H (R47H) in female P301S tauopathy mice to identify the pathways activated when AD risk is the strongest, thereby highlighting detrimental disease mechanisms. We find that R47H induces neurodegeneration in 9- to 10-month-old female APOE4 tauopathy mice. The combination of APOE4 and R47H (APOE4-R47H) worsened hyperphosphorylated tau pathology in the frontal cortex and amplified tauopathy-induced microglial cyclic guanosine monophosphate (GMP)-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling and downstream interferon response. APOE4-R47H microglia displayed cGAS- and BAX-dependent upregulation of senescence, showing association between neurotoxic signatures and implicating mitochondrial permeabilization in pathogenesis. By uncovering pathways enhanced by the strongest AD risk factors, our study points to cGAS-STING signaling and associated microglial senescence as potential drivers of AD risk.

Keywords: APOE; Alzheimer’s disease; R47H; TREM2; cGAS; inflammation; interferon; microglia; senescence; tau.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests L.G. is founder and equity holder of Aeton Therapeutics, Inc. S.C.S. is an equity holder and a consultant of Aeton Therapeutics, Inc. L.G. is scientific co-founder of Neurovanda and consults for Retro Biosciences. D.M.H. is an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Cajal Neuroscience and consults for Asteroid.

Update of

References

    1. Hansen DV, Hanson JE, and Sheng M. (2018). Microglia in Alzheimer’s disease. J Cell Biol 217, 459–472. 10.1083/jcb.201709069. - DOI - PMC - PubMed
    1. Nott A, Holtman IR, Coufal NG, Schlachetzki JCM, Yu M, Hu R, Han CZ, Pena M, Xiao J, Wu Y, et al. (2019). Brain cell type-specific enhancer-promoter interactome maps and disease-risk association. Science 366, 1134–1139. 10.1126/science.aay0793. - DOI - PMC - PubMed
    1. Schwabe T, Srinivasan K, and Rhinn H. (2020). Shifting paradigms: The central role of microglia in Alzheimer’s disease. Neurobiol Dis 143, 104962. 10.1016/j.nbd.2020.104962. - DOI - PubMed
    1. Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science 352, 712–716. 10.1126/science.aad8373. - DOI - PMC - PubMed
    1. Newcombe EA, Camats-Perna J, Silva ML, Valmas N, Huat TJ, and Medeiros R. (2018). Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease. J Neuroinflammation 15, 276. 10.1186/s12974-018-1313-3. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources